文献速递类风湿关节炎血管炎

血清胆固醇负载容量对巨噬细胞的作用与类风湿关节炎患者冠状动脉粥样硬化和心血管事件风险相关

Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis.
PubMed 文献 · RMD Open · 2022-01-01

在141例类风湿关节炎(RA)患者中,用CT血管造影评估冠状动脉粥样硬化,并前瞻性随访6.0±2.4年记录心血管事件。血清胆固醇负载容量(CLC)在调整ASCVD评分、他汀使用和低密度脂蛋白胆固醇后与整体斑块存在或负荷无关,但仅在未使用生物改善病情抗风湿药(bDMARD)者中与任何斑块、低衰减斑块和阻塞性斑块的存在及数量相关,且CLC与心血管事件风险相关(每增加1个标准差HR=1.76)。

要点

  • CLC在调整ASCVD评分、他汀使用和LDL-C后与整体斑块存在或负荷无关。
  • 仅在未使用bDMARD者中,CLC与任何斑块、低衰减斑块和阻塞性斑块的存在及数量相关(交互作用p≤0.018)。
  • CLC与心血管事件风险相关(每1 SD HR=1.76,95%CI 1.16-2.67,p=0.008),且bDMARD使用修饰此关联。

核心结论

  • CLC与RA患者的长期心血管事件风险相关,并在未使用bDMARD者中与高风险低衰减斑块和阻塞性冠状动脉斑块的存在及负荷相关。
  • 作者认为,CLC作为预测性生物标志物的前瞻性验证可能是有必要的。

研究设计与样本

  • 研究纳入141例RA患者,用CT血管造影评估冠状动脉粥样硬化(任何斑块、高风险低衰减斑块和阻塞性斑块)。
  • 参与者被前瞻性随访6.0±2.4年,记录心血管事件包括心源性死亡、心肌梗死、不稳定型心绞痛、卒中、跛行、血运重建和住院心力衰竭。
  • CLC通过患者血清孵育人巨噬细胞后定量细胞内胆固醇来测定。

主要发现

  • 调整ASCVD评分、他汀使用和低密度脂蛋白胆固醇后,CLC与整体斑块存在或负荷无关。
  • 仅在未使用bDMARD者中,CLC与任何斑块、低衰减斑块和阻塞性斑块的存在及数量相关(交互作用p≤0.018)。
  • 调整ASCVD和斑块节段数后,CLC与整体心血管事件风险相关(每1 SD HR=1.76,95%CI 1.16-2.67,p=0.008)。
  • bDMARD使用修饰CLC对事件风险的影响:未使用bDMARD者中CLC与事件相关(每1 SD HR=2.52,95%CI 1.36-4.65,p=0.003),使用bDMARD者中不相关。

局限性

  • 作者认为,CLC作为预测性生物标志物的前瞻性验证可能是有必要的。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: Cholesterol loading capacity (CLC) describes the ability of serum to deliver cholesterol to cells. It is linked to foam cell formation, a pivotal step in atherosclerotic plaque development. We evaluate the associations of CLC with coronary atherosclerosis presence, burden and cardiovascular risk in patients with rheumatoid arthritis (RA). METHODS: Coronary atherosclerosis (any, high-risk low-attenuation plaque and obstructive plaque) was evaluated with CT angiography in 141 patients. Participants were prospectively followed for 6.0±2.4 years and cardiovascular events including cardiac death, myocardial infarction, unstable angina, stroke, claudication, revascularisation and hospitalised heart failure were recorded. CLC was quantified as intracellular cholesterol in human macrophages after incubation with patient serum. RESULTS: CLC was not linked to overall plaque presence or burden after adjustments for atherosclerotic cardiovascular disease (ASCVD) score, statin use and low-density lipoprotein cholesterol. However, CLC associated with presence and numbers of any, low-attenuation and obstructive plaques exclusively in biologic disease-modifying antirheumatic drugs (bDMARD) non-users (p for interaction ≤0.018). CLC associated with cardiovascular event risk overall after adjustments for ASCVD and number of segments with plaque (HR=1.76 (95% CI 1.16 to 2.67) per 1 SD increase in CLC, p=0.008). Additionally, bDMARD use modified the impact of CLC on event risk; CLC associated with events in bDMARD non-users (HR=2.52 (95% CI 1.36 to 4.65) per 1SD increase in CLC, p=0.003) but not users. CONCLUSION: CLC was linked to long-term cardiovascular event risk in RA and associated with high-risk low attenuation and obstructive coronary plaque presence and burden in bDMARD non-users. Its prospective validation as a predictive biomarker may be, therefore, warranted.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Karpouzas GA, Papotti B, Ormseth S, et al. Serum cholesterol loading capacity on macrophages is linked to coronary atherosclerosis and cardiovascular event risk in rheumatoid arthritis. RMD Open. 2022. PMID: 36113961. doi:10.1136/rmdopen-2022-002411

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。